Avocații japonezi reprezentând victimele vaccinului HPV îndeamnă guvernul să interzi

[Adrian Pop]

Avocații japonezi reprezentând victimele vaccinului HPV îndeamnă guvernul să interzică vaccinurile HPV

July 3, 2018 1:17 pmJapanese-women-plaintiffs-HPV_2016In a recent press release commemorating the 5-year anniversary of the Japanese Government suspending its recommendation of the HPV vaccine, the National Attorneys Association for the HPV Vaccines Lawsuits called upon the Japanese Government to ban the HPV vaccine completely. This is the type of news that is routinely censored in the corporate-sponsored "mainstream" media in the United States. The fact that there is a national organization of attorneys litigating against one specific vaccine and the injuries it is causing, is itself newsworthy. The vaccine manufacturers who are being sued in Japan, GlaxoSmithKline PLC and Merck Sharp & Dohme Corp., enjoy 100% legal immunity in the United States, due to the 1986 National Childhood Vaccine Injury Compensation Act. We must look outside of the U.S., therefore, to learn about just how devastating Gardasil and the HPV vaccine is, as the National Association for the HPV Vaccines Lawsuits reports: "Compared to other routine vaccinations, an average of over seven times the number of serious adverse effects per one million HPV vaccinations have been reported, and the number of disability certifications by the Adverse Drug Reaction Relief System is almost ten times higher."



3 iulie 2018 1:17 pmJaponeză-femei-reclamanti-HPV_2016

Într-un comunicat de presă recunoscând aniversarea de 5 ani a guvernului japonez suspendând recomandarea sa de vaccin HPV, Asociația Națională de Avocați pentru procesele HPV Vaccinuri a cerut guvernului japonez să interzică complet vaccinul HPV.

Acesta este tipul de știri care este în mod obișnuit cenzurat în mass-media sponsorizate de corporații în Statele Unite. Faptul că există o organizație națională de avocați care se află în litigiu împotriva unui vaccin specific și a leziunilor pe care le provoacă, este el însuși informat.

Producătorii de vaccinuri care sunt dat în judecată în Japonia, GlaxoSmithKline PLC și Merck Sharp & Dohme Corp, se bucură de imunitate legală în Statele Unite, datorită Legii privind compensarea leziunilor provocate de vaccinul pentru copii în 1986.

Trebuie să privim în afara SUA, prin urmare, să aflăm despre cât de devastator este Gardasil și vaccinul împotriva HPV, așa cum relatează Asociația Națională pentru Vaccinurile împotriva HPV:

"În comparație cu alte vaccinări de rutină, o medie de șapte ori mai mare decât numărul au fost raportate efecte adverse grave la un milion de vaccinuri HPV, iar numărul de certificări privind dizabilitatea de către sistemul de ajutorare a reacțiilor adverse la medicamente este de aproape zece ori mai mare ".

Avocații japonezi reprezentând victimele vaccinului HPV îndeamnă guvernul să interzică vaccinurile HPV

[Adrian Pop]

http://vaccineimpact.com/2018/japanese-attorneys-representing-hpv-vaccine-victims-urge-government-to-ban-hpv-vaccines/

[Adrian Pop]

https://vaccineimpact.com/wp-content/uploads/sites/5/2017/11/Japanese-women-plaintiffs-HPV_2016.jpg
Comments by Brian Shilhavy
Editor, Health Impact News
In a recent press release commemorating the 5-year anniversary of the Japanese Government suspending its recommendation of the HPV vaccine, the National Attorneys Association for the HPV Vaccines Lawsuits called upon the Japanese Government to ban the HPV vaccine completely.
This is the type of news that is routinely censored in the corporate-sponsored “mainstream” media in the United States. The fact that there is a national organization of attorneys litigating against one specific vaccine and the injuries it is causing, is itself newsworthy.
The vaccine manufacturers who are being sued in Japan, GlaxoSmithKline PLC and Merck Sharp & Dohme Corp., enjoy 100% legal immunity in the United States, due to the 1986 National Childhood Vaccine Injury Compensation Act.
We must look outside of the U.S., therefore, to learn about just how devastating Gardasil and the HPV vaccine is, as the National Association for the HPV Vaccines Lawsuits reports:

Compared to other routine vaccinations, an average of over seven times the number of serious adverse effects per one million HPV vaccinations have been reported, and the number of disability certifications by the Adverse Drug Reaction Relief System is almost ten times higher.
Five Years Since the Suspension of Proactive Recommendation of the Human Papillomavirus (HPV) Vaccine in Japanby National Plaintiffs Association for the HPV Vaccines Lawsuits in Japan (https://www.hpv-yakugai.net/2018/06/29/5years-english/)
It has been five years since the Japanese Government halted proactive recommendation of the HPV vaccine on June 14, 2013, claiming that it could not provide the public with enough information.
Compared to other routine vaccinations, an average of over seven times the number of serious adverse effects per one million HPV vaccinations have been reported, and the number of disability certifications by the Adverse Drug Reaction Relief System is almost ten times higher.
The government has put in place research groups and selected cooperating medical institutions for the HPV vaccine, but measures to prevent adverse effects and to provide treatment have yet to be established.
The public cannot use the HPV vaccine with peace of mind.
The government officially endorsed the HPV vaccine nine years ago, and many of the victims who were junior or high school students at the time of their HPV vaccination have now grown into adults.
However, they have received no effective medical treatment until now and suffer from serious adverse effects, not only pain spreading all over their bodies and involuntary movements, but perceptual disorders, impaired mobility, sleep disruption, impaired memory, and learning disabilities.
While their classmates became working adults, they have been incapable of fully attending classes and have abandoned their plans for higher education or getting a job.
With no medical institutions able to give them sufficient treatment, they see no bright future and live under a shadow of uncertainty as they struggle to cope with agonizing symptoms every day.
Similar cases have been also reported overseas. Groups of victims from five countries, UK, Spain, Ireland, Colombia and Japan, participated in an international symposium held in Tokyo in March this year, and published a Joint Statement in April, calling for the necessity of a fact-finding investigation, development of treatment methods, and support for daily life, education and employment.
In the meantime, studies on the adverse effects of the HPV vaccine have made solid progress and a number of results have been reported. Based on analysis of multiple cases, one study clarified that the adverse effects of a range of symptoms develop in a multi-layered manner over time.
Another study reported changes in cerebrospinal fluid, cerebral blood flow, and peripheral nerves, etc.
A third study reported that the HPV vaccine causes impaired mobility among other effects in vaccinated mice due to neurological damage.
Finally, a fourth study indicated that individuals develop chronic ailments soon after receiving the HPV vaccine.
A paper written by researchers from the WHO Collaborating Centre for International Drug Monitoring argues that previous signal evaluations and epidemiological studies have relied primarily on reporting of a specific diagnosis or single-symptom concept, and thus a focus on symptomatology and seriousness in combination with an investigation of the underlying pathology may be required to fully elucidate the safety signals.
The drugmakers GlaxoSmithKline PLC and Merck Sharp & Dohme Corp. have long ignored this progress and insist on resuming proactive recommendation of the HPV vaccine, adding that the Global Advisory Committee on Vaccine Safety (GACVS) in WHO and other overseas authorities have already approved the safety of the HPV vaccine.
However, the epidemiological studies they rely on were not conducted with proper understanding of the adverse effects of the HPV vaccine and thus cannot be a basis for confirming safety.
It has also become clear that there are conflicts of interests and a lack of neutrality in WHO.
At the current time, the overall Japanese HPV vaccination rate has dropped to less than 1 percent, and few new cases have been reported from clinical practices, but new victims will obviously emerge if the government were to resume proactive recommendation of the HPV vaccine.
In January this year, although the government updated their HPV vaccine leaflets, those for girls to be vaccinated and their parents intentionally omit the risk of impaired memory and learning disabilities, delivering misleading information to the public.
Far from resuming proactive recommendation of the HPV vaccine, what the government must do now is to remove the HPV vaccine from its routine vaccination list.
We call again for the government and drugmakers not to spread harm any further, and demand that they compensate for all the harm caused based on their legal liabilities, and take the necessary measures to develop treatment methods and establish a medical treatment structure to prevent more suffering, so that victims can live in peace in the future.